Eleven-Year Survivor of Unresectable Intrahepatic Cholangiocarcinoma Treated Using Long-Term UFT Therapy

被引:0
作者
Takemura, Nobuyuki [1 ]
Kokudo, Norihiro [1 ]
Imamura, Hiroshi [1 ]
Takazawa, Yutaka [2 ]
Sano, Keiji [1 ]
Sugawara, Yasuhiko [1 ]
Nakagawa, Keiichi [3 ]
Ohtomo, Kuni [3 ]
Makuuchi, Masatoshi [1 ]
机构
[1] Univ Tokyo, Grad Sch Med, Dept Surg,Artificial Organ & Transplantat Div, Hepatobiliary Pancreat Surg Div,Bunkyo Ku, Tokyo 1138655, Japan
[2] Univ Tokyo, Dept Pathol, Tokyo 1138655, Japan
[3] Univ Tokyo, Dept Radiol, Tokyo 1138655, Japan
关键词
Tegafur-uracil (UFT); Intrahepatic cholangiocarcinoma; Long-term survival; Chemotherapy;
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We report a 49-year-old man with unresectable intrahepatic cholangiocarcinoma (ICC) who was treated with oral tegafur-uracil (UFT) chemotherapy and survived for over a decade. In 1995, the patient was admitted to our institution after a large tumor in his left liver was detected using computed tomography (CT). The tumor was diagnosed as ICC, and a laparotomy was performed; however, the tumor was too advanced to perform a curative resection. The cancer had spread to the lymph nodes in the hepatoduodenal ligament and on the posterior surface of the pancreas head. A curative resection was abandoned, and oral UFT chemotherapy was started immediately after the laparotomy. The tumor remained almost unchanged until 2001 with only UFT administration; however, its size gradually increased to 7.8 cm in diameter. External-beam radiotherapy (50.4 Gy) was performed, and the tumor's size decreased to 6.3 cm in diameter. Eleven years have now passed since the laparotomy, and the patient continues to lead a normal daily life working as a banker. The cumulative dose of UFT has reached 2511 g without any significant adverse effects. This case suggests that oral UFT might suppress the progression of ICC, contributing to this patient's 11-year survival period.
引用
收藏
页码:1997 / 1999
页数:3
相关论文
共 21 条
[21]  
Zeng ZC, 2006, CANCER J, V12, P113